#United States #New York #Levi & Korsinsky #Humacyte #HUMA

Important Class Action Reminder for Humacyte, Inc. Investors

Levi & Korsinsky, LLP has issued a notification regarding a pending class action lawsuit that affects shareholders of Humacyte, Inc. (NASDAQ: HUMA). If you invested in Humacyte during the specified period of alleged fraud, it's crucial to pay attention to the details outlined below.

Overview of the Suit

The lawsuit pertains to claims of securities fraud that occurred between May 10, 2024, and October 17, 2024. It aims to recover losses for investors who may have been adversely impacted by false representations made by the company. Notably, investors whose inquiries remain unanswered are encouraged to follow through with their claims by reaching out to the firm's representatives.

Key Allegations

The complaint points to several critical points of contention:
1. Regulatory Compliance Issues: It alleges that Humacyte's manufacturing facility in Durham, North Carolina, failed to adhere to good manufacturing practices, particularly in areas of quality control and microbial testing.
2. Delays in FDA Review: It claims that the company's issues necessitated a delay in the FDA's assessment of their biologics license application, hindering their progress.
3. Risk of FDA Approval: This situation raised concerns about the potential of receiving FDA approval for their acellular tissue-engineered vessel, which is crucial for vascular trauma treatments.
4. Deceptive Positive Statements: Due to these underlying problems, the company’s optimistic statements regarding its business and future prospects were misleading and lacked factual support.

What Should Investors Do?

Investors in Humacyte who believe they have incurred financial losses during the defined period should consider taking action before the January 17, 2025 deadline. This date marks the last opportunity for shareholders to file a motion to be appointed as lead plaintiffs in the case. However, it's important to note that participation in any recovery does not require becoming the lead plaintiff.

No Financial Liability

If you are a member of the class affected by this lawsuit, there are no costs associated with your participation. All fees related to the proceedings are typically covered, ensuring there’s no out-of-pocket expense for you.

Why Choose Levi & Korsinsky?

With more than two decades of experience in securities litigation, Levi & Korsinsky has a proven track record. They have won hundreds of millions for investors impacted by securities fraud and have been recognized as one of the top firms in the field, as endorsed by ISS Securities Class Action Services. Their team is comprised of over 70 experts dedicated to serving the needs of their clients effectively.

Contact Information

For further details, or if you wish to discuss your eligibility to participate, please contact:

• - Joseph E. Levi, Esq., Email: jlevi@zlk.com | Phone: (212) 363-7500
• - Ed Korsinsky, Esq. | 33 Whitehall Street, 17th Floor, New York, NY 10004

For more information regarding the class action suit and to submit a claim, please visit the firm’s dedicated page at Levi & Korsinsky.

Remaining proactive is vital for affected investors. Prioritize your rights as a shareholder by seeking the necessary legal support before the critical deadline passes.